文献速递淋巴瘤

ALYCANTE研究:不适合移植的大B细胞淋巴瘤患者二线axi-cel治疗后的健康相关生活质量

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

ALYCANTE是一项2期试验,评估高风险、不适合自体干细胞移植的复发/难治大B细胞淋巴瘤患者接受axi-cel后3个月完全代谢缓解率,并报告健康相关生活质量(HRQoL)次要终点。62例中60例完成基线及至少一次基线后HRQoL评估;输注后1个月躯体、角色、社会功能及疲乏出现临床显著恶化,但3个月时所有维度恢复,至12个月稳定或持续改善。探索性分析显示其HRQoL变化与ZUMA-7中适合移植患者相似或更优,3个月时整体健康状况和疲乏评分与同龄法国一般人群相当。

要点

  • axi-cel输注后1个月HRQoL在躯体、角色、社会功能及疲乏方面出现临床显著恶化。
  • 所有HRQoL维度在输注后3个月恢复,并至12个月保持稳定或持续改善。
  • 3个月时整体健康状况和疲乏评分与同龄法国一般人群相当。

核心结论

  • axi-cel可改善不适合移植的大B细胞淋巴瘤患者的HRQoL,支持其广泛人群应用。

研究设计与样本

  • 2期ALYCANTE试验(NCT04531046),纳入62例高风险复发/难治大B细胞淋巴瘤且不适合ASCT的患者。
  • HRQoL为次要终点,采用EORTC QLQ-C30、QLQ-NHL-HG29和EQ-5D-5L问卷在基线及输注后1、3、6、12个月评估。

主要发现

  • 62例中60例(97%)完成基线及至少1次基线后HRQoL评估。
  • 输注后1个月,躯体、角色、社会功能及疲乏的调整平均变化从基线出现超过临床阈值的显著恶化。
  • 输注后3个月所有HRQoL维度恢复,至12个月保持稳定或持续改善。
  • 探索性分析中,ALYCANTE的HRQoL调整平均变化与ZUMA-7中适合移植并接受axi-cel的患者相似或更优。
  • 输注后3个月,整体健康状况和疲乏评分改善至与同龄法国一般人群相当的水平。

临床怎么用

  • 对于不适合ASCT的高风险复发/难治大B细胞淋巴瘤患者,axi-cel二线治疗可考虑用于改善HRQoL。
  • 治疗早期(1个月内)可能出现功能及疲乏的临床显著恶化,需加强支持治疗并在3个月左右评估恢复情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axicabtagene ciloleucel (axi-cel) infusion as a primary end point in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation (ASCT). This study showed a significant improvement in complete metabolic response rate at 3 months based on historical controls. This study reports the health-related quality of life (HRQoL) results as a secondary end point. HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) cancer-specific questionnaire, the Quality of Life Questionnaire high-grade non-Hodgkin lymphoma 29 (QLQ-NHL-HG29) , and the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) generic questionnaire at baseline and 1, 3, 6, and 12 months after axi-cel infusion. Among the 62 patients included, 60 (97%) completed a baseline and at least 1 postbaseline HRQoL assessment. At 1 month infusion, adjusted mean change in HRQoL scores from baseline showed a clinically significant deterioration (greater than the clinical threshold) in physical, role, social functioning, and fatigue. However, all HRQoL dimensions recovered by 3 months after infusion and remained stable or continued to improve by 12 months. In an exploratory analysis, adjusted mean change in HRQoL score from baseline in ALYCANTE was similar to or better than in ASCT-eligible patients who received axi-cel in the phase 3 ZUMA-7 trial. Finally, the global health status and fatigue scores of the ALYCANTE population improved to levels comparable to the general French population of similar age by 3 months after infusion. These findings indicate that axi-cel improves HRQoL regardless of transplant eligibility, supporting its use across a broad patient population. This trial was registered at www.clinicaltrials.gov as #NCT04531046.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Charton E, Anota A, Bachy E, et al. Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma. Blood Adv. 2026. PMID: 41512176. doi:10.1182/bloodadvances.2025018057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。